[ad_1]
Notice of great interest for the C.OVID developed by company AstraZeneca together with the University of Oxford. The vaccine could become available for use in late December, the pharmaceutical manufacturer’s chief executive said. The company is now awaiting approval from regulatory authorities in the drug market.
The vaccine developed by this company entered the third phase of clinical trials in September but was temporarily suspended due to health concerns from a volunteer in the UK. Subsequently, they were resumed. AstraZeneca is considered one of the most promising candidates in the world in terms of the search for an effective anti-COVID-19 treatment.
S.andra Alexiu, president of the Bucharest-Ilfov Family Doctors Association and member of the vaccinology group of the National Society of Family Doctors, says this vaccine will be easier to administer than others currently in development.
“Several vaccines are in phase 3, in an advanced trial phase. It is being tested for 30,000 subjects and of which we already know some things. It is part of a series of vaccines already reserved and where will be approved“Alexiu said on Digi24.
“They will also arrive in Romania, we were told in a press release. It is one of the vaccines that will give us a little less transport and administration problems, because it is a vaccine that behaves much like the ones we use today. For the other vaccines in question, there was the question of special conditions for transport and administrationShe added.
“The Astra Zeneca vaccine, made with Oxford specialists, is a vaccine against adenovirus. This means that it uses an attenuated virus, somehow asleep, to introduce into the body that signal that stimulates the body to produce antibodies and which reacts to the encounter with the coronavirus. It is a two-dose administration, at least as is currently known, two doses at one-month intervals.
If it is released and this can happen, we and the EU will benefit, but some things need to be done. We must establish a good collaboration between all the actors involved in this, an excellent organization of vaccination, communication to the population and the establishment of risk groups. This is an important Desideratum, considering that we will not receive doses for the entire population, “Alexiu also said.
Publisher: Monica Bonea
.
[ad_2]
Source link
